Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma

European Urology

Volumn 40, Issue 3, 2001, Pages 294-299

  Oyen, W J G ^a   Witjes, J A ^a   Corstens, F H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone scan; FDG; Metastasis; Pain palliation; PET; Prostate carcinoma; Radionuclide imaging; Radionuclide therapy; Scintigraphy

Indexed keywords

HYDROXYETHYLIDENE DIPHOSPHONATE RHENIUM RE 186; LEXIDRONAM SAMARIUM SM 153; MONOCLONAL ANTIBODY; PENTETATE TIN SN 117M; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; STANAMET; STRONTIUM 89; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; CANCER THERAPY; HUMAN; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; HUMANS; MALE; NUCLEAR MEDICINE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035742174     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049789     Document Type: Article

References (49)

1. 99m Tc-labeled polyphosphate as a skeletal imaging agent
2. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer
3. Which patients with prostatic carcinoma require a staging bone scan?
4. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
5. Using prostate-specific antigen to eliminate the staging radionuclide bone scan
6. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer
7. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer
8. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate
9. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy
10. Follow-up in prostate cancer patients: Which parameters are necessary?
11. A new parameter for measuring metastatic bone involvement by prostate cancer: The Bone Scan Index
12. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer
13. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction
14. Dual-isotope protocol for indium-111 capromab pendetide monoclonal antibody imaging
15. Prostate cancer and prostate bed SPECT imaging with ProstaScint: Semiquantitative correlation with prostatic biopsy results
16. Comparison of clinical staging algorithms and indium-111-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high-risk prostate carcinoma patients
17. Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer
18. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients
19. 111-Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
20. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy
21. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide
22. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients
23. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
24. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody
25. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18-fluorine-labeled deoxyglucose
26. Fluorine-18-fluo-rodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy
27. PET imaging of prostate cancer using carbon-11-choline
28. Possible role of FDG-PET in the evaluation of urologic malignancies
29. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation
30. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG
31. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
32. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose
33. The management of intractable bone pain: A clinician's perspective
34. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases
35. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer
36. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy
37. Strontium 89 therapy for the palliation of pain due to osseous metastases
38. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
39. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomized controlled trial
40. Painful bone metastases in hormone-refractory prostate cancer: Economic costs of strontium-89 and/or external radiotherapy
41. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone
42. Re-186(Sn) HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone-resistant prostate cancer
43. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain
44. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer
45. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts
46. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial
47. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases
48. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: A phase I/II clinical study
49. Tin-117m(4+)DTPA: Pharmacokinetics and imaging characteristics in patients with metastatic bone pain